Book demo
Log in
Companies
Shukra Pharmaceuticals
Q4 24/25
Logotype for Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals (524632) Q4 24/25 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Shukra Pharmaceuticals Limited

Q4 24/25 earnings summary

6 Jun, 2025

Executive summary

  • Board approved audited standalone financial results for the quarter and year ended March 31, 2025, with unmodified audit opinion from statutory auditors.

  • Company operates in a single segment and reported results accordingly.

Financial highlights

  • Revenue from operations for FY25 was ₹3,258.73 lakhs, down from ₹7,457.29 lakhs in FY24.

  • Net profit for FY25 was ₹957.51 lakhs, a decrease from ₹1,853.72 lakhs in FY24.

  • Q4 FY25 revenue was ₹1,326.98 lakhs, up from ₹1,088.39 lakhs in Q4 FY24.

  • Q4 FY25 net profit was ₹538.64 lakhs, compared to ₹398.59 lakhs in Q4 FY24.

  • Earnings per share (EPS) for FY25 was ₹0.22, down from ₹4.23 in FY24.

Outlook and guidance

  • Auditors confirmed the company is a going concern with no material uncertainty regarding its ability to meet liabilities as they fall due.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Shukra Pharmaceuticals

View more events